Sen, Hilal SusamAtes, Belen TerlemezYilmazbas, PinarOcak, SuheylaKirimlioglu, HaleGokce, SelimAcarli, Koray2023-02-212023-02-212020-01-0110.24953/turkjped.2020.05.020https://hdl.handle.net/11443/1965http://dx.doi.org/10.24953/turkjped.2020.05.020Background. Kaposi's sarcoma (KS) is a complication of immunosuppressive therapy for transplant recipients. Unlike adult recipients, KS in pediatric organ transplantation is quite rare. Treatment is usually withdrawal of immunosuppressionnon-responders often receive chemotherapy. Case. We have reported a child with post-liver transplant visceral KS which has progressed despite withdrawal of immunosuppressive therapy, who has been treated with Paclitaxel for three weeks. KS has regressed completely after four cycles of Paclitaxel. Conclusion. Paclitaxel should be considered as an effective first line treatment option for patients with post-transplant KS.Kaposi's sarcomachildrenpaclitaxelArticleWOS:000582494600019